{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.questionFirstAnswered.=2017-07-14T13%3A59%3A38.78Z&tablingMemberConstituency=Jarrow", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-answer.questionFirstAnswered.=2017-07-14T13%3A59%3A38.78Z&tablingMemberConstituency=Jarrow", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.questionFirstAnswered.=2017-07-14T13%3A59%3A38.78Z&tablingMemberConstituency=Jarrow&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&min-answer.questionFirstAnswered.=2017-07-14T13%3A59%3A38.78Z&tablingMemberConstituency=Jarrow", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.questionFirstAnswered.=2017-07-14T13%3A59%3A38.78Z&tablingMemberConstituency=Jarrow", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.questionFirstAnswered.=2017-07-14T13%3A59%3A38.78Z&tablingMemberConstituency=Jarrow", "items" : [{"_about" : "http://data.parliament.uk/resources/1717662", "AnsweringBody" : [{"_value" : "Home Office"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1717662/answer", "answerText" : {"_value" : "
Detention plays a key role in maintaining effective immigration control and securing the UK\u2019s borders, particularly in connection with the removal of people who have no right to remain in the UK but who refuse to leave voluntarily.<\/p>
<\/p>
The Home Office takes the welfare and safety of people in its care very seriously and we are committed to ensuring the proper protection and treatment of people in detention.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4497", "label" : {"_value" : "Biography information for Michael Tomlinson"} } , "answeringMemberConstituency" : {"_value" : "Mid Dorset and North Poole"} , "answeringMemberPrinted" : {"_value" : "Michael Tomlinson"} , "dateOfAnswer" : {"_value" : "2024-05-16", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-16T13:35:15.933Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "1"} , "answeringDeptShortName" : {"_value" : "Home Office"} , "answeringDeptSortName" : {"_value" : "Home Office"} , "date" : {"_value" : "2024-05-13", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Immigration: Detainees"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for the Home Department, with reference to the Introduction to the Government Response to the Report of the European Committee for the Prevention of Torture and Inhuman or Degrading Treatment or Punishment (CPT) on its visit to the United Kingdom from 27 March to 6 April 2023 (CPT/Inf (2024) 09), whether he has had recent discussion with Cabinet colleagues on the implications for their policies of the (a) conditions of detention and (b) treatment of persons held under immigration powers in the UK.", "registeredInterest" : {"_value" : "true", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4783", "label" : {"_value" : "Biography information for Kate Osborne"} } , "tablingMemberConstituency" : {"_value" : "Jarrow"} , "tablingMemberPrinted" : [{"_value" : "Kate Osborne"} ], "uin" : "25992"} , {"_about" : "http://data.parliament.uk/resources/1716806", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1716806/answer", "answerText" : {"_value" : "
We are aware of the supply issues with the three enzyme replacement therapies, Creon 10,000 gastro-resistant capsules, Creon 25,000 gastro-resistant capsules, and Nutrizym 22 capsules. These are due to manufacturing and active pharmaceutical ingredient constraints. The Department will be issuing updated guidance to healthcare professionals regarding treatment of patients while there is a disruption to the supply of these pancreatic enzyme replacement therapies. We are having regular conversations with the suppliers of these products to help drive the resolution of these issues as quickly as possible, for example by expediting orders and increasing forecasts. We are also working with specialist importers to source unlicensed imports from abroad.<\/p>
Whilst we can\u2019t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-05-15", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "25370"} , {"_value" : "25371"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-15T08:18:01.063Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-05-09", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Enzyme Replacement Therapy"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, if she will make an assessment of the adequacy of the availability of enzyme replacement therapy.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4783", "label" : {"_value" : "Biography information for Kate Osborne"} } , "tablingMemberConstituency" : {"_value" : "Jarrow"} , "tablingMemberPrinted" : [{"_value" : "Kate Osborne"} ], "uin" : "25591"} , {"_about" : "http://data.parliament.uk/resources/1716571", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1716571/answer", "answerText" : {"_value" : "
We are aware of the supply issues with the three enzyme replacement therapies, Creon 10,000 gastro-resistant capsules, Creon 25,000 gastro-resistant capsules, and Nutrizym 22 capsules. These are due to manufacturing and active pharmaceutical ingredient constraints. The Department will be issuing updated guidance to healthcare professionals regarding treatment of patients while there is a disruption to the supply of these pancreatic enzyme replacement therapies. We are having regular conversations with the suppliers of these products to help drive the resolution of these issues as quickly as possible, for example by expediting orders and increasing forecasts. We are also working with specialist importers to source unlicensed imports from abroad.<\/p>
Whilst we can\u2019t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-05-15", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "25371"} , {"_value" : "25591"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-15T08:18:00.97Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-05-08", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Enzyme Replacement Therapy"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that people who require enzyme replacement therapy receive that medication in a timely manner.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4783", "label" : {"_value" : "Biography information for Kate Osborne"} } , "tablingMemberConstituency" : {"_value" : "Jarrow"} , "tablingMemberPrinted" : [{"_value" : "Kate Osborne"} ], "uin" : "25370"} , {"_about" : "http://data.parliament.uk/resources/1716572", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1716572/answer", "answerText" : {"_value" : "
We are aware of the supply issues with the three enzyme replacement therapies, Creon 10,000 gastro-resistant capsules, Creon 25,000 gastro-resistant capsules, and Nutrizym 22 capsules. These are due to manufacturing and active pharmaceutical ingredient constraints. The Department will be issuing updated guidance to healthcare professionals regarding treatment of patients while there is a disruption to the supply of these pancreatic enzyme replacement therapies. We are having regular conversations with the suppliers of these products to help drive the resolution of these issues as quickly as possible, for example by expediting orders and increasing forecasts. We are also working with specialist importers to source unlicensed imports from abroad.<\/p>
Whilst we can\u2019t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-05-15", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "25370"} , {"_value" : "25591"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-15T08:18:01.017Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-05-08", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Enzyme Replacement Therapy"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with pharmaceutical companies on ensuring adequate supplies of (a) enzyme replacement therapy and (b) other related medications.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4783", "label" : {"_value" : "Biography information for Kate Osborne"} } , "tablingMemberConstituency" : {"_value" : "Jarrow"} , "tablingMemberPrinted" : [{"_value" : "Kate Osborne"} ], "uin" : "25371"} , {"_about" : "http://data.parliament.uk/resources/1716222", "AnsweringBody" : [{"_value" : "Home Office"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1716222/answer", "answerText" : {"_value" : "
Healthcare services in immigration detention facilities in England are commissioned by NHS England. We take our responsibility towards detained individuals seriously and work closely with NHS England to ensure the health and safety of people we detain is safeguarded.<\/p>
<\/p>